Linlin Wang, Chunling Liu, Fangling Ning, Hongxu Liu, Jiuwei Cui, Wenzhong Su, Xiang Song, Yan Yang Wang, Qingshan Li, Yu Changhua, Xianping Cheng, Xiaomin Dang, Furong Hao, Tao Wei, Yang Wei, Huayuan Wang, Jie Wang, Xiusong Qiu, Xiaoyan Kang, Jinming Yu. "A double-blind, double-dummy, randomized, controlled phase 3 trial of iparomlimab and tuvonralimab (QL1706) vs QL1604 as consolidation therapy following concurrent or sequential chemoradiotherapy (cCRT/sCRT) in patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps8133